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Abstract
Over the past three years we have been involved in high-throughput screening in an effort to
discover novel small molecular modulators of aldehyde dehydrogenase (ALDH) activity. In
particular, we have been interested in both the activation and inhibitionof the three commonly
studied isoenzymes, ALDH1A1, ALDH2 and ALDH3A1, as their distinct, yet overlapping
substrate specificities, present a particularly difficult challenge for inhibitor discovery and design.
Activation of ALDH2 has been shown to benefit cardiovascular outcome following periods of
ischemia and renewed interest in specific inhibition of ALDH2 has application for alcohol
aversion therapy, and more recently, in cocaine addiction. In contrast, inhibition of either
ALDH1A1 or ALDH3A1 has application in cancer treatments where the isoenzymes are
commonly over-expressed and serve as markers for cancer stem cells. We are taking two distinct
approaches for these screens: in vitro enzyme activity screens using chemical libraries and virtual
computational screens using the structures of the target enzymes as filters for identifying potential
inhibitors, followed by in vitro testing of their ability to inhibit their intended targets. We have
identified selective inhibitors of each of these three isoenzymes with inhibition constants in the
high nanomolar to low micromolar range from these screening procedures. Together, these
inhibitors provide proof for concept that selective inhibition of these broad specificity general
detoxication enzymes through small molecule discovery and design is possible.
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1. Introduction
Aldehyde dehydrogenases catalyze the oxidation of a variety of endogenously generated and
exogenously encountered aldehydes and serve as enzymes designed to protect cells from the
damaging effects of these chemically reactive compounds [1,2]. Their diversity of
distribution and divergence finds them participating in the metabolism of a variety of
compounds, including amino acids, biogenic amines, vitamins, steroids and lipids [1,2].
These oxidation reactions occur concomitantly with the reduction of NAD(P)+ to NAD(P)H,
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depending on the specificity of the particular isoenzyme for the coenzyme type. In humans,
there are 18 known forms of the ALDH superfamily, some of which are highly specific for
their substrate, such as succinic semialdehyde dehydrogenase (ALDH4A1), and others that
possess broad substrate preferences for either aromatic (ALDH3A1) or aliphatic aldehydes
(ALDH1A1 or ALDH2) [3].
We have been trying to delineate both the metabolic roles for the broad substrate preference
enzymes (ALDH1A1, ALDH2 and ALDH3A1/2) and the mechanisms by which catalysis
occurs. While there is considerable evidence for the participation of ALDH2 in acetaldehyde
metabolism during ethanol oxidation [4], newer metabolic roles have been ascribed to
ALDH2 in pathways that protect cells during cardiac ischemia [5], trinitroglycerin
bioactivation [6-8] and cocaine addiction [9]. ALDH1A1 plays a role during acetaldehyde
metabolism, especially in ALDH2*2 individuals [4], and along with the related ALDH1A2
and ALDH1A3 forms likely contributes to retinoid metabolism [4,10-11]. Much recent
interest in ALDH1A1 is derived from the high levels of this enzyme in many tumor cells as
well as in cancer stem cells where it is often used as a marker enzyme for these cell types
[12-13]. Similarly, ALDH3A1 has garnered much interest over the years as its levels are
elevated in many tumors that demonstrate chemoresistance to cyclophosphamide derivatives
[14], as well as a playing a cytoprotective role against lipid peroxidation products [15].
Manipulation of ALDH3A1 expression levels in cell lines or its activity toward the cellular
metabolite correlates with their resistance to cyclophosphamides [16-17].
ALDH2 shares about 70% sequence identity to ALDH1A1 and only 30% sequence identity
to ALDH3A1. Like ALDH2, ALDH1A1 is a tetramer of identical 500 amino acid subunits
[18,19], but ALDH3A1 is a dimer of 453 amino acid subunits [20]. Given their distinct
substrate preferences and variable sequences, it is somewhat surprising that selective small
molecule inhibitors of these central detoxication and metabolic enzymes are available only
for the ALDH2 isoform [21-22]. In addition, the selective activation conferred by Alda-1 on
certain substrates, as well as its mode of binding when compared to daidzin, suggest that
selectivity can even be achieved at the level of distinct substrates for the same enzyme
[5,23]. To address this deficiency in chemical agonists/antagonists we have begun a series of
direct in vitro high-throughput screens and computational docking screens to discover novel
modulators of enzyme activity for ALDH2 and ALDH3A1. We report here the design of
these screens and the initial characterization of the compounds uncovered in these screening
procedures. In particular we have discovered a series of chemically distinct compounds that
show selectivity for ALDH2 and ALDH3A1 with IC50 values in the low micromolar to high
nanomolar range. In the future these initial lead compounds will be further characterized
through kinetic assays designed to determine their kinetic mechanism of action and through
direct structure determination bound to their respective target enzymes.
2. Materials and Methods
2.1. Expression of ALDH1A1, ALDH2 and ALDH3A1
ALDH1A1 and ALDH2 were prepared as described elsewhere [24,25]. The full-length
cDNA for human ALDH3A1 was purchased from Open Biosystems and subcloned into the
pET-28a expression plasmid and used to transform E. coli BL21 (DE3). The resulting cells
were grown in LB medium in the presence of kanamycin (50 μg/mL final concentration) at
37°C until absorbance at 600 nm reached 0.6. At that point, isopropyl β-D-
thiogalactopyranoside (IPTG; 0.1 mM final concentration) was added to induce the
synthesis of ALDH3A1, and the cells were incubated for an additional 16 hours at 16°C, and
collected by centrifugation.
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2.2. Purification of ALDH3A1
The cell pellets were resuspended in Buffer A (20 mM sodium HEPES, 300 mM NaCl pH
7.8, 2 mM benzamidine, 1 mM beta-mercaptoethanol) and lysed by passage through a
French Press operated at 13,000 psi. The lysate was clarified by centrifugation at 100,000xG
for 45 minutes at 4°C in a Beckman Ti45 rotor. The lysate supernatant was loaded onto a
nickel-NTA column and the fractions were eluted using Buffer B (20 mM sodium HEPES,
300 mM sodium chloride, 500 mM imidazole pH 7.8, 2 mM benzamidine, 1 mM beta-
mercaptoethanol). The eluted fractions from the nickel column were analyzed by SDS gel to
confirm the presence of ALDH3A1 protein. Those fractions containing protein were pooled
and dialyzed against two changes of Buffer C (10 mM sodium HEPES pH 7.8, 1 mM
benzamidine, 1 mM sodium EDTA, and 1 mM dithiothreitol) at 4°C. The dialyzed fractions
were loaded onto a Q-sepharose column equilibrated in Buffer C and were eluted using
Buffer D (10 mM sodium HEPES, 250 mM NaCl, pH 7.8, 1 mM benzamidine, 1 mM EDTA
and 1 mM dithiothreitol). Fractions containing the ALDH3A1 protein were once again
pooled and dialyzed against Buffer E (10 mM sodium HEPES pH 7.8, 1 mM dithiothreitol)
at 4°C. The dialyzed protein was concentrated using a protein concentrator operated with
30,000 Dalton molecular weight cutoff membrane. The concentrated protein was filtered and
its concentration and specific activity was determined before flash freezing aliquots in liquid
N2 and storing at −80°C.
2.3. Activity assay for ALDH3A1
The activity of ALDH3A1 was measured using two different methods – oxidation of
benzaldehyde and hydrolysis of para-nitrophenylacetate. The dehydrogenase activity was
assayed spectrophotometrically on a Beckman DU-640 by monitoring the increase in
absorbance at 340 nm due to NADPH formation (molar extinction coefficient of 6,220
M−1cm−1) in a solution containing 6.8 nM of ALDH3A1, 1 mM benzaldehyde and 1.5 mM
NADP+ in 100 mM sodium phosphate buffer, pH 7.5. The esterase activity was assayed
spectrophotometrically by monitoring the formation of para-nitrophenol at 405 nm (molar
extinction coefficient of 18,000 M−1cm−1) in a solution containing 180 nM ALDH3A1, and
0.8 mM para-nitrophenylacetate in 25 mM sodium HEPES buffer, pH 7.5. All assays were
initiated by the addition of substrate, following a preincubation with inhibitors for 2 minutes.
2.4. Computational docking procedures for ALDH2
The crystal structure of ALDH2 was obtained from the RCSB Protein Data Bank (PDB
code: 1o05). The solvent molecules in the apo-enzyme crystal structure were removed. The
protein was protonated with the Reduce (26) (version3.03) program to optimize the H-bond
interactions and potential steric clashes. The ALDH2 structure was further processed using
AutoDockTools (27) (version 1.5.0) to assign Gasteiger charges and was converted to a
united atom model. Affinity grids encompassing the active site, delineated at one end by
Glu399 (adjacent to the nicotinamide ribose binding site) and the other end by the main-
chain atoms of Phe459 (at the solvent exposed end of the substrate access tunnel), were
calculated using AutoGrid4 with the spacing of 0.375 Å. The ChemDiv dataset was obtained
from ZINC7 database (28). A total of 500,000 compounds using AutoDock4 (29) program
were docked to ALDH2. The receptor was kept rigid while the ligands were allowed to
move freely during the docking process. Ligand conformational search space was explored
employing the Lamarckian genetic algorithm. Each compound was docked 10 times and the
binding pose with the lowest binding energy was saved. The binding pose of each compound
was further rescored with three additional scoring functions (ChemScore, GOLD and PMF)
using the SYBYL8.0 (Tripos, St. Louis, MO) CScore module. Top compounds were
clustered by chemical similarity using Openbabel (version 2.2.0) and analyzed with the
PyMOL visualization program (Version 1.2r3pre, Schrödinger, LLC). This resulted in the
selection of 112 compounds that were purchased and tested for activity in vitro.
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2.5. ALDH1A1 and ALDH2 activity assays
The dehydrogenase activity was screened by measuring the rate of increase in the
fluorescence of NADH upon propionaldehyde oxidation in 50 mM sodium BES at pH 7.5
containing 50 μM NAD+ and 50 μM propionaldehyde at 25 °C. The changes in fluorescence
were monitored over a 7-minute period through excitation at 350 nm and emission at 465
nm with a Tecan Ultra384 plate reader. Negative control reactions contained 2% (v/v)
dimethylsulfoxide (DMSO) and the positive control reaction for inhibition contained 50 μM
daidzin. IC50 values were determined by varying the concentration of the small molecules
from 0 to 100 μM under the same reaction conditions. The esterase activity was assayed by
measuring the rate of para-nitrophenol formation at 405 nm in 25 mM sodium BES, pH 7.0
on a Spectromax Plus 384 plate reader over a 7-minute period. Esterase assays utilized 0.8
mM para-nitrophenylacetate as a standard substrate concentration and enzyme
concentrations of 0.06 μM for ALDH2 and 2% DMSO in all assay conditions. All kinetic
data were analyzed with SigmaPlot (v10.0, StatSys). All assays with inhibitors were
preincubated with enzyme and NAD+ for 2 minutes before initiating the reactions with
substrate. The inhibition data were fit to the four parameter EC50 equation. All data
represent the average of a minimum of three independent experiments with at least two
different enzyme preparations. IC50 values were determined by varying the concentration of
the small molecules from 0 to 100 μM.
2.6 High-throughput screening on ALDH3A1 and further validation of inhibitors
The chemical library was composed of 101,000 compounds, among which 64,000 were from
ChemDiv Corp. and 37,000 were from ChemBridge Corp. All the compounds were present
in 10 μL aliquots in 2% DMSO at 50 μM concentration in a 384 well plate format.
Screening was done on 384 well clear bottom plates using the esterase assay by monitoring
the absorbance of para-nitrophenol at 405 nm wavelength in a 50 μL assay containing 180
nM ALDH3A1, 0.8 mM para-nitrophenylacetate, 10 μM library compound, 2% DMSO and
25 mM sodium HEPES buffer, pH 7.5 (all final concentrations) on a Spectromax Plus 384
plate reader over a 10-minute period.
Compounds that showed more than 60% inhibition in the primary screen were taken for
secondary screening to validate the inhibition. Compounds whose inhibition replicated were
further tested for their ability to inhibit the dehydrogenase, assayed with the Beckman
DU-640 UV-Vis spectrophotometer. IC50 values were further determined for the inhibitors
that inhibited both dehydrogenase and esterase activities of ALDH3A1. The inhibition data
were fit to the four parameter EC50 equation using SigmaPlot (v10.0, StatSys). All data
represent the average of a minimum of three independent experiments with at least two
different enzyme preparations. Basic selectivity for the inhibitors was tested using the
ALDH1A1 and ALDH2 enzymes. ALDH1A1 and ALDH2 activities were assayed
spectrophotometrically by monitoring the absorbance at 340 nm in a solution containing 1.5
mM NAD+, 200 μM propionaldehyde, 10 μM inhibitors, 0.16 μM of enzyme, in 25 mM
sodium BES buffer, pH 7.5. Compounds that strongly inhibited ALDH3A1 and only
minimally inhibited ALDH1A1 and ALDH2 were selected.
3. Results and Discussion
3.1. ALDH2 screen
The top scoring 112 compounds from the computational screening procedure were chosen
for further studies, of these 90 were available from ChemDiv. The 90 available compounds
were screened for their ability to inhibit the dehydrogenase activity of hALDH2. The
compounds were added to the assay at a final concentration of 50 μM, and the activity
relative to ALDH2 without added inhibitor, but containing 2% (v/v) DMSO as the negative
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control reaction was measured (Figure 1). Daidzin at 50 μM was included as a positive
control for inhibition. Compounds were selected for further evaluation if they reduced the
activity of ALDH2 by more than 60%, relative to the negative control reaction (Figure 1).
The 19 compounds that inhibited hALDH2 propionaldehyde oxidation by more than 60%
were then tested for their potency in inhibiting both propionaldehyde oxidation and ester
hydrolysis. From the list of 19 inhibitory compounds 5 compounds were identified that
exhibited IC50 values less than 25 μM for either reaction (Table 1). In particular, three
structurally related compounds were retained in this list (I74, I76, and I78) that could inhibit
both activities of hALDH2 with IC50 values less than 5 μM. I72 is of interest as its
inhibition activity was specific to aldehyde oxidation, with no inhibitory activity measurable
toward the esterase reaction, suggesting that its site of action might overlap more completely
with the coenzyme binding site, which is not required for ester hydrolysis. Under the
conditions of screening and IC50 assays (sub-saturating for NAD+, but saturating for
propionaldehyde), I76 is more potent than even the positive control daidzin (Table 1), which
is the most selective ALDH2 inhibitor widely available, though a more selective compound
based on daidzin is now emerging [9,22].
Future study of these compounds will focus on determining their respective mechanisms of
inhibition (competitive, non-competitive or uncompetitive) when varied against either
coenzyme or aldehyde concentrations, as well as direct structure determination on
complexes between these compounds and ALDH2. In addition, we are in the process of
analyzing analogs of I32, I72, and I76 to build a detailed structure/activity relationship for
each of the compounds. Given that I74, I76 and I78 are structural analogs of each other and
possess the best binding characteristics we will begin our work with these analogs. This
work demonstrates that ALDH2 is robust model for computational approaches to inhibitor
discovery and that inhibitors with sub-micromolar potency can be identified using this
technique. However, since all 112 of the top scoring compounds possess similar docking
scores, appropriately designed in vitro assays are still required to identify true positives in
the list of potential inhibitors.
3.2. ALDH3 screen
For high throughput screening, we used an assay system based on the inherent esterase
activity of ALDH3. The esterase assay was selected for the primary screening assay because
the absorbance of para-nitrophenol at 405 nm has minimal spectral overlap with the
absorbance characteristics of the majority of compounds in the chemical library. In addition,
the catalytic requirements for ester hydrolysis overlap with those required for
propionaldehyde oxidation. Using an inhibition cutoff of 60% inhibition, the primary screen
yielded 71 compounds for further evaluation. Rescreening of these compounds using
benzaldehyde oxidation as the assay yielded 55 inhibitors that inhibited ALDH3A1 in both
assays. All of the active compounds had molecular masses ranging between 300 and 600
daltons; some sharing the same core structures. The independent identification of
compounds with similar core structure provides confidence that our screen has identified
genuine ALDH3A1 inhibitors. These 55 compounds were classified into 11 different
categories based on their structures, though some compounds were unique and lacked
structural homologs in the initial lead inhibitor list. We determined IC50 values for both the
benzaldehyde oxidation and ester hydrolysis reactions dehydrogenase and esterase assay for
the best inhibitor prototype within each class of inhibitor (Table 2). From these initial assay
results we identified 14 compounds with IC50 values less than 20 μM and several with IC50
values below 1 μM (Table 2).
To assess the potential selectivity of these lead inhibitor compounds we tested their ability to
inhibit aldehyde oxidation of both ALDH1A1 and ALDH2. None of the inhibitors from the
ChemDiv collection (CD compound identifiers, Table 3) showed isoenzyme selectivity.
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However three inhibitors from the ChemBridge collection (CB compound identifiers)
showed less than 10% inhibition of ALDH1A1 or ALDH2 at 10 μM concentration
(compounds CB7, CB25 and CB29, Table 3). Future work will characterize the mechanism
of inhibition for these compounds versus varied coenzyme and benzaldehyde concentrations.
In addition, we have initiated crystallographic investigations of the human ALDH3A1
enzyme in order to provide structural insight into the selectivity and potency of these initial
lead inhibitory molecules.
In conclusion, we have initiated high-throughput approaches designed to identify novel and
selective small molecules that affect catalysis in the human ALDH2 and ALDH3A1
isoenzymes. We have identified several promising lead compounds using both
computational and in vitro enzyme assay approaches. Future work will more fully
characterize their mechanisms of inhibition and chemical features that contribute to their
inhibitory potency and isoenzyme selectivity.
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Figure 1. Results from the Primary Dehydrogenase Inhibition Screen for ALDH2
The bar graphs represent the average level of inhibition of ALDH2 activity for each of the
putative inhibitors from three independent assays. The uninhibited reaction (− Control) is set
to 0% inhibition in this figure, while the positive control reaction (+ Control) contained 50
μM daidzin. The horizontal dashed line set at 60% inhibition illustrates the cutoff value used
to select compounds for further evaluation.
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Table 2
IC50 values for the structurally diverse inhibitors.§
Compounds
Library ID (Dehydrogenase assay)
IC50 (μM)
(Esterase assay)
IC50 (μM)
CD4 4896-2649 2.5 2.9
CD5 4896-2665 1.5 1
CD8 5353-0801 6.3 2.2
CD10 6148-0105 3.4 1.3
CD11 6148-0270 10.2 18.8
CD12 6148-0271 5.6 10.4
CD15 8015-2991 7.3 0.8
CB7 5613645 0.2 2.6
CB12 5787580 4.1 0.2
CB15 6046772 2 0.3
CB20 6378722 1 0.1
CB25 6505720 2 0.4
CB29 6632949 5 0.5
CB34 6997087 0.5 0.2
§
ALDH3A1 assays were treated with different concentrations of inhibitors. Each value represents the concentration of inhibitor at which enzyme
activity reduces to half the maximal activity.
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Table 3
Isoenzyme selectivity for the most potent inhibitors.*
Compounds ALDH1A1 activity ALDH2 activity ALDH3A1 activity
CD4 × √ √
CD5 √ √ √
CD8 √ √ √
CD10 √ √ √
CD11 √ √ √
CD12 √ √ √
CD15 √ √ √
CB7 × × √
CB12 × √ √
CB15 √ × √
CB20 √ √ √
CB25 × × √
CB29 × × √
CB34 √ × √
*
Inhibitors were tested for their specificity against ALDH1A1 and ALDH2 catalyzed dehydrogenase activity at 10 μM concentration of inhibitor.
Check marks indicate greater than 15% inhibition of the indicated isoenzyme, whereas x’s indicate less than 10% inhibition of the indicated
isoenzyme.
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